{"filings":[{"id":2033761,"accession_number":"0001326110-26-000077","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-08-04T11:36:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Q2 net product revenue $50.7M, up 92% YoY; eighth consecutive quarter of growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $50.7M in Q2 2026, up 92% YoY and 15% sequentially; first-half revenue $94.8M, up 121% YoY.","Cash and marketable securities $357.4M as of June 30, 2026; adjusted net loss improved to $81.0M from $89.9M YoY.","FDA accepted sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease; PDUFA Jan 6, 2027.","UAE granted broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC.","Exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG in NMIBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1970316,"accession_number":"0001326110-26-000071","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-07-30T21:19:45+00:00","items":["7.01","9.01"],"status":"ready","headline":"ImmunityBio gets UAE marketing authorization for ANKTIVA in bladder and lung cancers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UAE approved ANKTIVA for BCG-unresponsive NMIBC (CIS and papillary) and metastatic NSCLC after checkpoint failure.","NMIBC CIS cohort (N=100): 71% complete response rate; median DoR 26.6 months, with responses beyond 54 months.","Papillary-only cohort (N=80): 12-month disease-free survival 58.2%; 83.1% cystectomy-free at 36 months.","NSCLC checkpoint-refractory (N=79): median OS 14.6 months; 16.2 months in patients with ALC ≥1,000.","Authorization expands ANKTIVA's global regulatory footprint to 34 countries; validity through July 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":975318,"accession_number":"0001326110-26-000064","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-06-10T21:24:02+00:00","items":["5.07","9.01"],"status":"ready","headline":"ImmunityBio 2026 annual meeting: all directors re-elected, Deloitte ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nine directors, including Patrick Soon-Shiong, re-elected with average ~730M 'for' votes.","Ratification of Deloitte & Touche as auditor for FY2026 passed: 882M 'for', 1.7M 'against'.","Approximately 885M shares (85% of outstanding) represented at the June 9, 2026 meeting.","Broker non-votes of 151.5M shares occurred on director elections (non-discretionary items)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":501636,"accession_number":"0001193125-26-229153","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-05-18T21:20:47+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ImmunityBio signs exclusive U.S. supply agreement with Japan BCG Laboratory for Tokyo strain of BCG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement grants ImmunityBio exclusive U.S. rights to develop and commercialize Tokyo-172 BCG for 10 years after FDA approval.","Positive Phase III SWOG S1602 trial demonstrated non-inferiority of Tokyo strain vs TICE BCG in high-grade NMIBC (HR 0.82; 95.8% CI 0.63–1.08).","ImmunityBio plans to engage FDA for BLA submission as sole applicant; no payment due until FDA approval; vials for regulatory submission provided at no cost.","Agreement provides second BCG source alongside Serum Institute's rBCG; rBCG remains available to eligible patients under FDA Expanded Access Program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92131,"accession_number":"0001326110-26-000057","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Q1 net product revenue $44.2M, up 168% YoY; ANKTIVA approvals expand; cash $381M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net product revenue $44.2M, up 168% YoY ($16.5M) and 15% sequentially from Q4 2025 ($38.3M).","ANKTIVA unit sales up 168% YoY; approved in 5 jurisdictions covering ~34 countries, including first Asia approval in Macau.","Cash and marketable securities $380.9M as of March 31, 2026, up from $242.8M at Dec 31, 2025.","Pivotal BCG-naïve CIS trial fully enrolled; sBLA submission on track for 2026.","GAAP net loss $632.8M driven by non-cash fair value changes; adjusted net loss $86.2M vs $82.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":44206000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92130,"accession_number":"0001326110-26-000036","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio reports preliminary Q1 2026 net product revenue $44.2M, up 168% YoY, cash $381M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q1 2026 net product revenue ~$44.2M, up 168% YoY and 15% sequentially from $38.3M in Q4 2025.","Cash, cash equivalents and marketable securities of $380.9M as of March 31, 2026.","ANKTIVA unit sales volume increased 168% YoY; now approved in 5 jurisdictions covering ~34 countries.","NCCN guidelines updated March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC papillary-only disease (Category 2A).","Pivotal BCG-naive NMIBC CIS trial (QUILT-2.005) fully enrolled; supplemental BLA submission on track for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92129,"accession_number":"0001193125-26-142932","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ImmunityBio submits response to FDA OPDP Warning Letter; outlines corrective actions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted comprehensive response to FDA OPDP Warning Letter dated March 13, 2026.","Identified podcast removed from corporate website; requested removal from third-party platforms.","TV advertisement cited in FDA letter was never broadcast or disseminated to the public.","Implementing enhanced compliance: executive training, expanded PRC protocols, external regulatory counsel.","CEO Richard Adcock reaffirms commitment to accurate and compliant promotional communications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102729,"accession_number":"0001193125-26-133363","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"ImmunityBio secures $75M non-dilutive RIPA financing; $25M note conversion reduces debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Additional $75M under Revenue Interest Purchase Agreement (RIPA) with Oberland Capital; total committed capital $375M.","Royalty payback rate increased to tiered 5.625%-12.5% of net sales; cap at 195% of cumulative payments.","Proceeds to support global expansion, pipeline advancement, and general corporate purposes.","Nant Capital converted $25M of convertible note into 4,606,596 shares; note outstanding now $480M.","Recent ANKTIVA approvals in US, UK, EU, Saudi Arabia, Macau; covering ~34 countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102728,"accession_number":"0001326110-26-000025","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio reports 700% YoY revenue growth to $113M; first lung cancer approval in Saudi Arabia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 ANKTIVA net product revenue $113M (up ~700% YoY); Q4 net revenue $38.3M (up 431% YoY).","Unit sales volume increased 750% in 2025 vs 2024; cash and securities $242.8M as of Dec 31, 2025.","SFDA granted conditional accelerated approval for ANKTIVA + checkpoint inhibitors in metastatic NSCLC (Jan 2026) – first lung cancer approval globally.","Global regulatory footprint expanded to 33 countries across 4 jurisdictions (US, UK, EU, Saudi Arabia) in under two years.","Net loss attributable to common stockholders narrowed to $351.4M in 2025 from $413.6M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":113288000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102727,"accession_number":"0001326110-26-000018","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio gets EC approval for ANKTIVA+BCG in NMIBC CIS; now authorized in 33 countries","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC conditional marketing authorization for ANKTIVA+BCG in BCG-unresponsive NMIBC CIS; 71% complete response rate, median DOR 26.6 months.","Approval covers all 27 EU member states plus Iceland, Norway, Liechtenstein; total authorized countries now 33.","First immunotherapy authorized in Europe for this indication; prior standard of care was radical cystectomy.","Authorization based on QUILT-3.032 phase 2/3 trial; ImmunityBio to submit long-term safety and efficacy data as condition.","Global regulatory footprint built in under 2 years from initial FDA approval in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102726,"accession_number":"0001326110-26-000014","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ImmunityBio amends $505M convertible note to allow partial conversion at any time","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Convertible note amendment allows holder Nant Capital to convert any portion of $505M principal into common stock at any time before maturity.","Previously, partial conversion was not permitted under the December 2024 note; no other terms changed.","Holder Nant Capital is an affiliate of Executive Chairman Dr. Patrick Soon-Shiong, making this a related-party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102725,"accession_number":"0001326110-26-000008","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio reports preliminary FY2025 ANKTIVA revenue ~$113M, up ~700% YoY, and Saudi approval for NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2025 net product revenue ~$113.0M, ~700% YoY increase; Q4 2025 revenue ~$38.3M, up 20% QoQ and 431% YoY.","ANKTIVA unit sales volume grew 750% in 2025 vs 2024; quarter-over-quarter unit growth 54% during FY2025.","Saudi FDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC (first global approval for this indication) and + BCG for NMIBC CIS.","Phase 2b QUILT-2.005 trial enrollment ahead of expectations; full enrollment anticipated in H1 2026.","Estimated cash, cash equivalents and marketable securities of $242.8M as of Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":113288000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102724,"accession_number":"0001326110-26-000004","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Saudi FDA grants accelerated approval for ImmunityBio's ANKTIVA in NSCLC and NMIBC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SFDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC after standard-of-care failure; first worldwide approval for this subcutaneous IL-15 agonist.","Approval based on QUILT-3.055 and QUILT-2.023 showing lymphocyte recovery and survival association; confirmatory trial ResQ-201A recruiting.","SFDA also approved ANKTIVA + BCG for BCG-unresponsive NMIBC with CIS, adding to U.S., U.K., and conditional EU approvals.","ImmunityBio plans regional office in Saudi Arabia and partner Biopharma Cigalah for MENA commercial distribution; NMIBC trial enrollment ahead of schedule, BLA submission by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118962,"accession_number":"0001193125-25-331244","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ImmunityBio expands ATM equity offering capacity by $460M; authorized shares increased by 300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to ATM agreement with Jefferies LLC authorizes up to $459.97M in additional common stock sales.","Board and stockholders approved increase in authorized common shares from 1.35B to 1.65B, effective Nov 10, 2025.","ATM sales will be made under existing S-3ASR shelf registration and prospectus supplement dated Dec 23, 2025.","Amendment also updates settlement to T+1 and modifies auditor comfort letter delivery requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118961,"accession_number":"0001326110-25-000146","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ImmunityBio appoints Bruce Wendel to board of directors effective Dec. 12.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Wendel appointed independent director effective Dec. 12, 2025; term expires at 2026 annual meeting.","Background includes Abraxis BioScience (commercialized Abraxane, led Celgene acquisition), Bristol-Myers Squibb.","Receives $50k annual cash retainer plus initial stock option with $300k Black-Scholes value, vesting 1/3 annually over 3 years.","Previously served on boards of GT BioPharma and Verastem."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118960,"accession_number":"0001326110-25-000143","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio receives EMA positive opinion for ANKTIVA+BCG in NMIBC CIS in Europe","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA recommends conditional marketing authorization for ANKTIVA+BCG to treat BCG-unresponsive NMIBC with CIS.","Decision based on single-arm trial: 71% complete response rate, median duration ~27 months (up to 54+ months).","Over 150,000 Europeans diagnosed with NMIBC annually; no authorized treatment currently for BCG-unresponsive cases.","Opinion forwarded to European Commission for final EU-wide approval; company to submit long-term follow-up data.","Six BCG strains available in Europe; ImmunityBio developing recombinant BCG to address U.S. shortages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118959,"accession_number":"0001326110-25-000138","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Q3 product revenue up 434% YoY to $31.8M; net loss narrows to $67.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $31.8M in Q3 2025 vs $6.0M in Q3 2024; YTD sales $74.7M (+434%).","ANKTIVA unit volumes up 467% YTD 2025 vs FY2024; net loss attributable to common $67.3M (vs $85.7M).","Cash and securities $257.8M at Sep 30, 2025, up from $153.7M at Jun 30, 2025.","Early glioblastoma combo study: 100% disease control (2 near-complete responses, 3 stable).","Phase 3 NSCLC trial (ResQ201A) initiated; ANKTIVA named preferred drug by ~80M-life organization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":75003000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135510,"accession_number":"0001193125-25-177024","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio reaches preliminary settlement in shareholder derivative lawsuit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court preliminarily approved derivative settlement on July 29, 2025, with final hearing set for Nov 4, 2025.","Settlement requires ImmunityBio to adopt corporate governance reforms including a new independent director and enhanced compliance.","Attorneys' fees not to exceed $1.4 million will be paid by insurance; no monetary payment to shareholders.","Governance reforms include quarterly board updates on FDA/cGMP compliance and annual legal department reviews.","Settlement resolves derivative actions related to alleged oversight failures and misleading statements about Anktiva BLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135509,"accession_number":"0001326110-25-000112","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Q2 revenue jumps 60% to $26.4M; net loss narrows to $92.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $26.4M, up 60% from Q1 and from $990k in Q2 2024; YTD sales $42.9M.","Net loss $92.6M ($0.10/share) vs $134.6M in Q2 2024; operating loss narrowed.","Cash $153.7M at June 30; $80M equity financing closed July 2025 with potential $96M warrant proceeds.","UK MHRA approved ANKTIVA for BCG-unresponsive NMIBC; FDA refused to file sBLA for papillary-only NMIBC, company re-evaluating.","ANKTIVA unit volume grew 246% in 1H 2025 vs 2H 2024 since J-code approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":42942000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135508,"accession_number":"0001193125-25-164789","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"ImmunityBio raises $80M equity; Q2 revenue $26.4M (+60% QoQ), ANKTIVA units up 246%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 29.6M shares and warrants at $2.70/unit, gross proceeds ~$80M.","Q2 2025 revenue $26.4M, up 60% from Q1 2025; year-to-date sales ~$43M.","Cash and equivalents $153.7M as of June 30, 2025.","FDA refused to file supplemental BLA for papillary NMIBC; company re-evaluating approach with new data.","UK MHRA approved ANKTIVA marketing authorization; NSCLC RCT initiated in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152503,"accession_number":"0001326110-25-000084","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ImmunityBio stockholders approve 2025 Equity Incentive Plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 Equity Incentive Plan approved; reserves 46,088,027 new shares plus up to 32,359,674 from expired/forfeited 2015 Plan awards.","All eight director nominees re-elected at June 18, 2025 annual meeting; 89% of shares represented.","Deloitte & Touche ratified as independent auditor for fiscal 2025 with 99.5% votes in favor.","Plan replaces 2015 Plan; no further awards under prior plan, but existing grants continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152502,"accession_number":"0001326110-25-000069","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Reports Q1 2025 Net Product Revenue of $16.5M, Up 129% from Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue for Q1 2025 reached $16.5 million, a 129% increase over $7.2 million in Q4 2024.","ANKTIVA unit sales volume grew 150% in Q1 2025 compared to Q4 2024, with March volume up 69% over February.","Nearly 200 urology practices are registering for ImmunityBio's recombinant BCG Expanded Access Program (EAP).","Positive long-term results from the QUILT 3.032 study showed highest cystectomy avoidance in NMIBC space.","ImmunityBio completed a $75 million equity financing in April 2025 to support operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":16517000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152501,"accession_number":"0001193125-25-112057","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio receives FDA refusal to file for ANKTIVA sBLA in NMIBC papillary indication","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Refusal to File (RTF) letter on May 2, 2025 for sBLA of ANKTIVA+BCG in BCG-unresponsive papillary NMIBC.","Company cites unanimous January 2025 FDA leadership guidance encouraging sBLA submission; RTF called inconsistent.","Existing approval for CIS +/- papillary (Cohort A) is unaffected; RTF pertains to papillary without CIS (Cohort B).","Data highlighted: 96% disease-specific survival at 36 months and >82% bladder-sparing rate in the papillary cohort.","Company requests urgent Type A meeting with FDA; former FDA Principal Deputy Commissioner Dr. Sherman supports appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152500,"accession_number":"0001326110-25-000044","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Q1 net product revenue ~$16.5M (+129% QoQ); submits sBLA for NMIBC papillary disease","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net product revenue ~$16.5M (+129% QoQ from $7.2M in Q4 2024).","Unit sales volume in Q1 2025 grew 150% QoQ exceeding FY2024 total; March up 69% MoM.","Submitted sBLA to FDA for ANKTIVA+BCG in BCG-unresponsive NMIBC papillary disease; 93% cystectomy avoidance at 20.7 months.","Submitted Expanded Access Protocol (EAP) for ANKTIVA to treat lymphopenia after RMAT designation in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":16517000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152499,"accession_number":"0001193125-25-075102","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ImmunityBio raises $75M in registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$75M from sale of 29.0M shares and warrants; warrants exercisable at $3.101 for 5 years.","Offering priced at $2.584 per share plus warrant; expected close April 9, 2025.","If fully exercised, warrants could yield additional ~$90M in gross proceeds.","Single institutional investor; securities offered under existing shelf registration.","Use of proceeds: working capital and support ongoing business operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171321,"accession_number":"0001326110-25-000040","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ImmunityBio replaces auditor EY with Deloitte for fiscal year 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Ernst & Young as independent auditor on March 13, 2025; no disagreements or reportable events.","Deloitte & Touche appointed as new independent auditor for fiscal year ending Dec 31, 2025, subject to client acceptance.","EY provided a letter (Exhibit 16.1) agreeing with the company's disclosures in this 8-K.","Company did not consult Deloitte on accounting principles during the two most recent fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171320,"accession_number":"0001326110-25-000031","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Q4 net product revenue $7.2M; Feb ANKTIVA units up 67% MoM; RMAT designation granted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $7.2M in Q4 2024, up 21% QoQ from $6.0M in Q3; full-year net product revenue $14.2M.","ANKTIVA February 2025 unit sales up 67% month-over-month from January; Jan+Feb combined exceed total Q4 2024 units.","Permanent J-code (J9028) issued Jan 2025; FDA authorized expanded access of rBCG with over 45,000 vials available and 60+ sites activating.","MAAs for ANKTIVA+BCG accepted by MHRA and EMA in Feb 2025; RMAT designation for ANKTIVA+PD-L1 t-haNK in pancreatic cancer.","Net loss attributable to common stockholders narrowed to $59.2M in Q4 2024 from $233.4M in Q4 2023; cash and securities $149.8M at Dec 31."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171319,"accession_number":"0001193125-25-025324","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ImmunityBio approves executive compensation: 2024 bonuses, 2025 equity grants, salary increases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2024 cash bonuses paid at 80% of target: Soon-Shiong $372,600, Adcock $477,600, Sachs $230,143; payable March 14, 2025.","2025 LTIP RSU grants: Soon-Shiong 822,368, Adcock 822,368, Sachs 246,710; vest ratably over 3 years.","Option grants at $3.39 strike: Soon-Shiong 2,812,500 NQSO, Adcock 2,812,500 ISO, Sachs 843,750 ISO.","2025 base salaries effective March 10: Soon-Shiong $652,050, Adcock $835,800, Sachs $592,619."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171318,"accession_number":"0001193125-25-022776","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John Owen Brennan resigns from ImmunityBio board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Owen Brennan resigned from the Board and all committees effective February 7, 2025.","Resignation was not due to any dispute with the Company regarding operations, policies, or practices.","Mr. Brennan had served as a director since 2021.","Company expressed appreciation for his service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188314,"accession_number":"0001193125-24-274871","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ImmunityBio prices $100M public offering at $3/sh and restructures $505M Nant Capital note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Public offering of 33.3M shares at $3/sh for gross proceeds ~$100M; net to company ~$93.1M from firm shares.","Underwriters have 30-day option to purchase additional 5M shares at $3/sh; potential net proceeds $107.2M.","Concurrent debt restructuring: Nant Capital notes consolidated into $505M note due Dec 2027, interest SOFR+8%, convertible at $5.427/sh.","Limited consent from Oberland Capital (RIPA) obtained for the debt restructuring.","Net proceeds intended for ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, R&D, working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188313,"accession_number":"0001193125-24-274438","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio announces public offering and $505M debt restructuring with Nant Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposed public offering of common stock; Jefferies & Piper Sandler lead; 30-day option for 15% additional shares.","Contingent on offering, Nant Capital converts $230M notes into ~116.5M shares; remaining $505M note due 2027 at SOFR+8%.","Enters Limited Consent and Amendment to Revenue Interest Purchase Agreement with Oberland consenting to restructuring.","Shareholder derivative action filed Nov 20, 2024 in Delaware Chancery challenging Sept 2023 financing with Dr. Soon-Shiong.","Net proceeds to fund ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188312,"accession_number":"0001326110-24-000115","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio reports 71% complete response rate in 100-patient ANKTIVA trial; durable responses up to 54 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100 patients with BCG-unresponsive NMIBC CIS enrolled; 71% achieved complete response (CR) rate.","Durable response duration ranged up to 54 months in responders, supporting cystectomy avoidance.","Updated data to be submitted to EMA in Marketing Authorization Application in Q4 2024.","CR rate consistent with 71% reported for 82 patients in NEJM Evidence (Chamie 2022).","Study continues to monitor durability of responses and overall survival outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188311,"accession_number":"0001326110-24-000109","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImmunityBio Q3 product revenue $6.0M, net loss narrows; ANKTIVA J-code set for Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $6.0M from ANKTIVA launch in Q3, up from $1.0M in Q2; diluted EPS -$0.14 vs -$0.19 YoY.","Permanent J-code for ANKTIVA issued, effective Jan 1, 2025; medical coverage for over 200M lives secured.","MAA submitted to UK MHRA for ANKTIVA; EU submission planned in Q4 2024, covering 30 countries.","Cash and marketable securities $130.4M as of Sept 30; net loss attributable to stockholders -$85.7M vs -$95.6M YoY.","ANKTIVA shelf life extended to 3 years; over 125,000 doses available for market and trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":7193000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204786,"accession_number":"0001326110-24-000093","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ImmunityBio settles IP lawsuit with HCW, acquires TGFb trap assets and licenses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves arbitration and federal lawsuit with HCW Biologics; no monetary consideration from ImmunityBio.","ImmunityBio receives ownership of IP and drug candidates HCW9218, HCW9219, HCW9209 for TGFb-related fusion proteins.","HCW9218 is a bifunctional fusion protein (TGFb trap + IL-15) studied in Phase 1/1b trials for ovarian and pancreatic cancer.","ImmunityBio also gets exclusive license to use TF Platform for oncology targets PDL-1, IL-7, IL-12, IL-18, IL-21, plus one more.","Parties exchange mutual releases; ImmunityBio to dismiss arbitration after compliance with settlement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221634,"accession_number":"0001326110-24-000069","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ImmunityBio annual meeting: directors re-elected, equity plan shares increased by 19.9M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees re-elected, including Patrick Soon-Shiong, with over 556M votes For each.","Amendment to increase authorized shares under 2015 Equity Incentive Plan by 19.9M shares approved (547M For).","Say-on-pay advisory vote approved with 556.7M For votes.","Ratification of Ernst & Young as auditor for FY2024 ratified (606.9M For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221633,"accession_number":"0001326110-24-000040","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ImmunityBio gets FDA approval for ANKTIVA in BCG-unresponsive NMIBC; CR rate 62%, DOR >47 months","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ANKTIVA (N-803) plus BCG for BCG-unresponsive NMIBC with CIS on April 22, 2024.","Complete response rate of 62% in evaluable patients; duration of complete response >47 months and ongoing.","58% of patients had DOR ≥12 months, 40% had DOR ≥24 months; median DOR not yet reached.","ANKTIVA expected to be available in U.S. by mid-May 2024; conference call April 26 at 11am EDT.","Company plans to seek approval to increase shares under 2015 Equity Incentive Plan by up to 19.9M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241182,"accession_number":"0001193125-24-044886","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["5.02","5.05"],"status":"ready","headline":"ImmunityBio awards $805K bonuses, 3.2M options, RSUs; sets 2024 exec pay","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["2023 bonuses: Soon-Shiong $232,875, Adcock $298,500, Sachs $273,980; payable by March 15, 2024.","Option grants: Soon-Shiong 1.19M NSOs, Adcock 1.59M ISOs, Sachs 424K ISOs at $5.24 strike.","RSU grants: Soon-Shiong 342,987, Adcock 457,317, Sachs 121,951; vest ratably over 3 years.","2024 salary/target bonus: Soon-Shiong $621K/75%, Adcock $796K/75%, Sachs $575K/50%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241181,"accession_number":"0001326110-24-000003","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"ImmunityBio secures up to $320M royalty and equity financing from Oberland Capital; $210M funded at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$200M non-dilutive royalty financing closed; additional $100M contingent on FDA approval of Anktiva for NMIBC (PDUFA Apr 23, 2024).","$10M equity private placement at $4.11/share; Oberland gets 5-year option for another $10M.","Nant Capital $505M notes extended to Dec 2025; conversion option at 75% premium to market.","Total 2023 capital raised reaches $850M; proceeds to fund commercialization and pipeline.","Royalty rate: initially 3%-7% of net sales (ex-China); capped at 195% of investment; may step down to 1.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275954,"accession_number":"0001326110-23-000121","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"ImmunityBio restructures $470M in debt; gets $200M new capital from founder","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $200M convertible note to Nant Capital (founder affiliate) with 3-yr term, convertible at 50% premium to market price.","Exchanged $270M of existing debt for 209,291,936 shares of common stock, deleveraging balance sheet.","Extended $535M in debt maturities from Dec 2023 to Dec 2024.","Net proceeds of ~$199M to fund regulatory, pre-commercialization for Anktiva (N-803) in bladder cancer.","All transactions are related-party with Dr. Patrick Soon-Shiong, Executive Chairman and Global CSMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275953,"accession_number":"0001326110-23-000112","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio subsidiary to enforce settlement as Sorrento fails to pay judgments","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Sorrento failed to pay judgments held by NantCell and NANTibody by August 31, 2023 deadline.","NantCell and NANTibody to deliver certification of non-payment by September 6, triggering settlement terms.","Upon certification, mutual release of claims, release of judgments, and Sorrento relinquishes NANTibody interests.","Sorrento forfeits rights to payments from antibody license including royalties from PD-L1 t-haNK NK cell therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275952,"accession_number":"0001326110-23-000102","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bankruptcy court approves Sorrento settlement; two scenarios could resolve ImmunityBio litigation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Bankruptcy court approved settlement on Aug 14, 2023 between ImmunityBio and Sorrento (Case No. 23-90085).","Scenario A: If Sorrento raises funds by Aug 31, it pays judgments to NantCell and NANTibody and can proceed with litigation.","Scenario B: If not, judgments released, Sorrento relinquishes interests in NANTibody and forfeits antibody license rights.","As of June 30, 2023, ImmunityBio had recorded no receivables on the judgments; outcome remains uncertain.","Settlement includes release of derivative litigation in Los Angeles Superior Court; now binding on parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275951,"accession_number":"0001193125-23-190800","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ImmunityBio closes $40M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 14,569,296 shares at $2.7455 per share with warrants for 14,569,296 shares at $3.2946.","Gross proceeds of ~$40M before fees; Jefferies as placement agent at 6% fee.","Warrants are immediately exercisable and expire 3 years from issuance.","Closing expected July 25, 2023, subject to customary conditions.","February 2023 warrants amended to match new warrants' exercise price and 3-year term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275950,"accession_number":"0001193125-23-190491","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio updates Sorrento settlement terms; securities class action filed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sorrento settlement hearing set for Aug 14, 2023; two scenarios: pay judgments by Aug 31 or release claims and relinquish NANTibody interests.","If settlement not approved, ImmunityBio will continue pursuing judgment collection; no receivables recorded as of June 30, 2023.","Securities class action filed June 30, 2023 in S.D. Cal. alleging false statements re FDA complete response letter for Anktiva (N-803).","Company believes class action is without merit and intends to defend vigorously; cannot estimate potential loss.","FDA CRL cited deficiencies at third-party contract manufacturers; BLA for N-803 + BCG for bladder cancer not approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293579,"accession_number":"0001326110-23-000076","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["1.01","2.03","5.07","9.01"],"status":"ready","headline":"ImmunityBio signs $30M promissory note with Nant Capital (SOFR+8%, due Dec 31, 2023)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Three $10M advances available; interest at Term SOFR + 8% per annum payable quarterly.","Net proceeds ~$29.85M after $150k origination fee (0.5%) paid to lender.","Proceeds to fund pre-commercialization, clinical development, R&D, capex, and general corporate purposes.","Lender Nant Capital is affiliate of Executive Chairman Dr. Patrick Soon-Shiong (related-party transaction).","Annual meeting results: all nine director nominees re-elected; Ernst & Young ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293578,"accession_number":"0001326110-23-000063","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA rejects ImmunityBio's BLA for Anktiva (N-803) in bladder cancer; CRL cites manufacturing issues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Complete Response Letter for Anktiva (N-803) + BCG in BCG-unresponsive NMIBC with CIS.","Deficiencies relate to pre-license inspection of third-party contract manufacturing and additional CMC issues.","No new preclinical or Phase 3 studies requested; FDA wants updated duration-of-response data and safety update.","Executive Chairman provides $30M non-convertible debt financing (SOFR+8%, matures Dec 31, 2023).","Partnering discussions for commercialization continue with a large biopharma; no assurance of completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314213,"accession_number":"0001326110-23-000028","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ImmunityBio issues $30M convertible promissory note to Nant Capital, LLC","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$30M principal, Term SOFR + 8% interest, due Dec 31, 2023.","Investor is Nant Capital, LLC, affiliated with Executive Chairman Dr. Patrick Soon-Shiong.","Net proceeds $29.85M after 0.5% origination fee; funds for pre-commercialization, R&D, and corporate purposes.","Convertible at holder's option after next insider trading window opens at greater of Nasdaq closing or bid price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314212,"accession_number":"0001326110-23-000023","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio provides N-803 BLA update with May 23 PDUFA, reports NSCLC OS data, and notes S1800D closure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BLA for N-803+BCG in BCG-unresponsive NMIBC with CIS; PDUFA date May 23, 2023; approval uncertain.","QUILT 3.055 NSCLC pooled analysis (N=86) shows median OS 13.9 months vs historical 6-7.5 months.","SWOG/NCI S1800D study (N-803+pembrolizumab) closed early for not meeting 60% disease control at 12 weeks.","Company exploring partnering for N-803 intravesical commercialization and potential financing from Executive Chairman.","Board appointed Cheryl L. Cohen as Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314211,"accession_number":"0001193125-23-039833","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ImmunityBio raises $50M via registered direct offering, issues shares and warrants to institutional investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$50M from sale of 14,072,615 shares and warrants; warrants could yield up to $60M more if fully exercised.","Purchase price $3.5530 per share with accompanying warrant; warrant exercise price $4.2636, expires in 2 years.","Jefferies LLC acts as exclusive placement agent; receives 6% cash fee on gross proceeds.","Proceeds intended for working capital and ongoing business operations.","Closing expected on or about February 17, 2023, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314210,"accession_number":"0001193125-23-039399","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"ImmunityBio reports estimated cash and securities of $108M as of Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary estimate of cash, cash equivalents and marketable securities as of Dec 31, 2022: approximately $108.0M.","Includes $104.6M cash & equivalents and $3.4M marketable securities.","These are preliminary estimates; final results may differ and will be in Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314209,"accession_number":"0001326110-23-000014","cik":1326110,"company_name":"ImmunityBio, Inc.","ticker":"IBRX","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ImmunityBio obtains $176.4M judgment against Sorrento confirmed by court; $159.4M payable to subsidiary","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["LA County Superior Court confirms $176.37M arbitration award against Sorrento; $159.42M payable to ImmunityBio subsidiary NantCell.","Court grants injunction barring Sorrento from overseas transfers >$1M and insider transfers until award is paid.","Judgment includes 10% post-judgment interest; arbitrator previously awarded $173.5M with prejudgment interest.","ImmunityBio intends to pursue collection vigorously but provides no assurance on full recovery or timing.","Other disputes between ImmunityBio affiliates and Sorrento remain pending; Company will defend claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8313895942.336882,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-13T23:59:59+00:00|314209"}